Related Experiment Video

Updated: Jul 19, 2026

High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors
19:02

High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors

Published on: March 22, 2011

Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor

Luciano Di Croce1, Veronica A Raker, Massimo Corsaro

  • 1Department of Experimental Oncology, European Institute of Oncology, Milan, Italy. ldicroce@lar.ieo.it

Science (New York, N.Y.)
|February 9, 2002
PubMed

Insights

The PML-RAR fusion protein causes gene silencing through DNA hypermethylation, driving leukemia. Retinoic acid reverses this, highlighting epigenetic changes in cancer development.

Area of Science:

  • Molecular biology
  • Cancer research
  • Epigenetics

Background:

  • DNA methylation is a key mechanism for silencing tumor suppressor genes in cancer.
  • The precise molecular mechanisms dictating DNA methylation specificity remain largely unknown.
  • Aberrant DNA methylation patterns are hallmarks of malignant transformation.

Purpose of the Study:

  • To elucidate the molecular mechanisms by which the PML-RAR fusion protein induces gene hypermethylation and silencing.
  • To investigate the role of PML-RAR-mediated hypermethylation in leukemogenesis.
  • To determine if targeting DNA demethylation can reverse the transformed phenotype.

Main Methods:

  • Investigated the recruitment of DNA methyltransferases (DNMTs) to target gene promoters by the PML-RAR fusion protein.
  • Assessed the impact of PML-RAR-induced hypermethylation on gene expression and cellular transformation.
  • Utilized retinoic acid treatment to induce promoter demethylation and observe phenotypic reversion.

Main Results:

  • The PML-RAR fusion protein actively recruits DNA methyltransferases to specific gene promoters, leading to gene hypermethylation and transcriptional silencing.
  • This PML-RAR-induced hypermethylation was found to contribute significantly to the protein's leukemogenic potential.
  • Treatment with retinoic acid resulted in promoter demethylation, restoration of gene expression, and reversion of the transformed cellular phenotype.

Conclusions:

  • Established a direct mechanistic link between genetic alterations (PML-RAR fusion) and epigenetic changes (DNA hypermethylation) in cancer development.
  • Demonstrated that DNA hypermethylation induced by PML-RAR is a critical factor in the early stages of carcinogenesis.
  • Showcased retinoic acid as a potential therapeutic agent capable of reversing oncogenic epigenetic modifications.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells12:04

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

Related Concept Videos

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...